Boehringer Ingelheim Targets KRAS Mutations with Lupin’s LNP3794
By Pratika Pahwa & Michelle Liu
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 21 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2462 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing to expand its footprint in the oncogenic KRAS mutations space, Boehringer Ingelheim has entered into a licensing, development and commercialisation agreement with Lupin for LNP3794, a mitogen-activated protein kinase inhibitor...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS